Trial Profile
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SBRT-IL2
- 24 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 23 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 23 Sep 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.